swisspartners Ltd. acquired a new position in shares of Kintara Therapeutics, Inc. (NASDAQ:KTRA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 275,000 shares of the company’s stock, valued at approximately $479,000.
Separately, Envestnet Asset Management Inc. purchased a new position in shares of Kintara Therapeutics in the 1st quarter valued at $27,000. Institutional investors own 6.75% of the company’s stock.
KTRA traded up $0.04 on Friday, reaching $1.79. The company had a trading volume of 28 shares, compared to its average volume of 1,064,248. Kintara Therapeutics, Inc. has a 1 year low of $0.61 and a 1 year high of $3.35. The company has a market cap of $58.39 million, a PE ratio of -0.82 and a beta of 1.45. The stock’s 50-day simple moving average is $1.47.
About Kintara Therapeutics
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
Want to see what other hedge funds are holding KTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kintara Therapeutics, Inc. (NASDAQ:KTRA).
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.